HK1255584A1 - 使用阿坎酸及d-环丝胺酸的联合疗法 - Google Patents

使用阿坎酸及d-环丝胺酸的联合疗法 Download PDF

Info

Publication number
HK1255584A1
HK1255584A1 HK18114711.9A HK18114711A HK1255584A1 HK 1255584 A1 HK1255584 A1 HK 1255584A1 HK 18114711 A HK18114711 A HK 18114711A HK 1255584 A1 HK1255584 A1 HK 1255584A1
Authority
HK
Hong Kong
Prior art keywords
cycloserine
acamprosate
combination therapy
patient
therapeutic agent
Prior art date
Application number
HK18114711.9A
Other languages
English (en)
Chinese (zh)
Inventor
Steven L. JOHNS
Craig A. ERICKSON
Original Assignee
Confluence Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals, Llc filed Critical Confluence Pharmaceuticals, Llc
Publication of HK1255584A1 publication Critical patent/HK1255584A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK18114711.9A 2015-08-04 2016-08-04 使用阿坎酸及d-环丝胺酸的联合疗法 HK1255584A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200864P 2015-08-04 2015-08-04
US62/200,864 2015-08-04
PCT/US2016/045547 WO2017024129A1 (en) 2015-08-04 2016-08-04 Combination therapy using acamprosate and d-cycloserine

Publications (1)

Publication Number Publication Date
HK1255584A1 true HK1255584A1 (zh) 2019-08-23

Family

ID=57944041

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114711.9A HK1255584A1 (zh) 2015-08-04 2016-08-04 使用阿坎酸及d-环丝胺酸的联合疗法

Country Status (11)

Country Link
US (2) US20180221315A1 (enExample)
EP (1) EP3331518A4 (enExample)
JP (2) JP2018526345A (enExample)
KR (1) KR20180034442A (enExample)
AU (2) AU2016303610A1 (enExample)
CA (1) CA2993614A1 (enExample)
HK (1) HK1255584A1 (enExample)
IL (1) IL257035A (enExample)
SG (1) SG10201914045QA (enExample)
WO (1) WO2017024129A1 (enExample)
ZA (1) ZA201800558B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331518A4 (en) * 2015-08-04 2019-04-03 Confluence Pharmaceuticals, LLC COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN
US12042566B2 (en) 2017-05-17 2024-07-23 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
CA3064846A1 (en) 2017-05-25 2018-11-29 Glytech, Llc Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
JP2025069475A (ja) * 2022-03-08 2025-05-01 ソシウム株式会社 Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤
WO2024224537A1 (ja) * 2023-04-27 2024-10-31 ソシウム株式会社 筋萎縮性側索硬化症の治療又は予防剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1073432T3 (da) * 1998-04-14 2007-12-17 Gen Hospital Corp Anvendelse af D serin eller D alanin til behandling af skizofreni
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2167068A2 (en) * 2007-07-05 2010-03-31 Inserm-Institut National De La Sante Et De La Recherche Medicale Anticonvulsive pharmaceutical compositions
SI2395990T1 (sl) * 2009-02-12 2015-04-30 Indiana University Research And Technology Corporation Offic Of Technology Transfer Snov in postopki za zdravljenje razvojne motnje, vključno s komorbidnim in idiopatskim avtizmom
WO2010099217A1 (en) * 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013002584A2 (ko) * 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
EP3331518A4 (en) * 2015-08-04 2019-04-03 Confluence Pharmaceuticals, LLC COMBINATION THERAPY WITH ACAMPROSATE AND D-CYCLOSERIN

Also Published As

Publication number Publication date
EP3331518A1 (en) 2018-06-13
US20180221315A1 (en) 2018-08-09
JP2018526345A (ja) 2018-09-13
EP3331518A4 (en) 2019-04-03
KR20180034442A (ko) 2018-04-04
WO2017024129A1 (en) 2017-02-09
IL257035A (en) 2018-03-29
AU2016303610A1 (en) 2018-02-01
AU2022202218A1 (en) 2022-04-21
US20200360316A1 (en) 2020-11-19
JP2021152060A (ja) 2021-09-30
SG10201914045QA (en) 2020-03-30
CA2993614A1 (en) 2017-02-09
ZA201800558B (en) 2019-10-30

Similar Documents

Publication Publication Date Title
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12016502355B1 (en) Pharmaceutical composition
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
WO2016090024A3 (en) Combination therapy for treatment of cancer
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
EP3590338A3 (en) Medical treatments based on anamorelin
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
NZ724285A (en) Agent for improving or preventing progression of chronic kidney disease
HK1233917A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy